HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
•
***
This stock is shown as delisted in our database.
***
If you think this isn't correct then please
let us know
Tranzyme is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal (GI) motility disorders. GI motility disorders are conditions which disrupt the normal movement of food throughout the GI tract. Tranzymes two most advanced product candidates, ulimorelin, which is in Phase 3, and TZP-102, which is entering Phase 2b, are being evaluated for the treatment of predominantly upper GI motility disorders. Approximately 20 percent of adults worldwide are affected by conditions these product candidates are designed to treat. While upper GI motility disorders are a highly prevalent group of persistent and recurring conditions, there are currently a limited number of treatment options for patients suffering from these conditions. In addition to ulimorelin and TZP-102, Tranzyme is also developing a motilin antagonist, TZP-201, for the treatment of various forms of moderate-to-severe diarrhea, and a ghrelin antagonist, TZP-301, for the treatment of obesity and other metabolic diseases.
Q4 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
No data found for this quarter. | ||||||
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
GRAIS LINDA S PRESIDENT AND CEO |
|
0 | 2017-12-11 | 0 |
|
0 | 2017-12-11 | 0 | |
|
0 | 2017-12-11 | 0 | |
BYRNES MICHAEL CFO AND TREASURER |
|
0 | 2017-12-11 | 0 |
BUKOFZER STAN CHIEF MEDICAL OFFICER |
|
0 | 2017-12-11 | 0 |
|
0 | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
|
No longer subject to file | 2017-12-11 | 0 | |
THOMAS, MCNERNEY & PARTNERS, LLC THOMAS, MCNERNEY & PARTNERS II L.P. |
|
No longer subject to file | 2017-01-30 | 0 |
|
0 | 2016-12-31 | 0 | |
AGGARWAL GAURAV CHIEF BUSINESS OFFICER |
|
20,000 | 2016-01-15 | 0 |
PATNI RAJIV CHIEF DEVELOPMENT OFFICER |
|
5,050 | 2015-05-07 | 0 |
|
47,963 | 2015-01-01 | 0 | |
TETLOW SHARON ACTING CFO & TREASURER |
|
3,000 | 2014-07-11 | 0 |
|
0 | 2014-06-11 | 0 | |
|
0 | 2014-06-11 | 0 | |
SOFINNOVA VENTURE PARTNERS VI L P SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG SOFINNOVA VENTURE AFFILIATES VI LP |
|
No longer subject to file | 2014-03-18 | 0 |
ROUSSEAU FRANCK CHIEF MEDICAL & DEV OFFICER |
|
0 | 2013-12-19 | 0 |
|
0 | 2013-12-19 | 0 | |
HILLEMAN JERYL L CFO AND SECRETARY |
|
0 | 2013-12-19 | 0 |
|
No longer subject to file | 2013-07-15 | 0 | |
|
988,285 | 2013-07-15 | 0 | |
|
7,333 | 2013-07-15 | 0 | |
|
1,565,463 | 2013-07-15 | 0 | |
|
15,731 | 2013-07-15 | 0 | |
|
47,963 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
1,588,857 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
1,629,157 | 2013-07-15 | 0 | |
|
47,963 | 2013-07-15 | 0 | |
MCGOWAN DANA S. CFO AND SECRETARY |
|
0 | 2013-07-15 | 0 |
|
2,438,569 | 2013-07-15 | 0 | |
|
2,438,569 | 2013-07-15 | 0 | |
|
2,438,569 | 2013-07-15 | 0 | |
STANLEY RHONDA L. CONTROLLER |
|
0 | 2013-01-04 | 0 |
EISENSTADT RICHARD I VP, FINANCE & CFO |
|
0 | 2012-08-07 | 0 |
THOMAS HELMUT SENIOR VP, R&D |
|
0 | 2012-08-07 | 0 |
|
0 | 2012-08-07 | 0 | |
GARG VIPIN K PRESIDENT & CEO |
|
0 | 2012-08-07 | 0 |
|
0 | 2012-08-07 | 0 | |
|
0 | 2012-08-07 | 0 | |
MOORE DAVID VP, COMMERCIAL OPERATIONS |
|
0 | 2012-04-19 | 0 |
|
57,704 | 2012-03-12 | 0 | |
|
2,328,863 | 2012-03-12 | 0 | |
|
232,011 | 2012-03-12 | 0 | |
KOSUTIC GORDANA VP, CLINICAL AND REGULATORY |
|
0 | 2011-04-19 | 0 |
|
0 | 2011-04-19 | 0 | |
|
2,564,791 | 2011-04-06 | 0 | |
|
8,986,358 | 2011-04-06 | 0 | |
|
No longer subject to file | 2011-04-06 | 0 | |
|
3,002,291 | 2011-04-06 | 0 | |
|
No longer subject to file | 2011-04-06 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|